Daiichi Sankyo Inc., the US subsidiary of Daiichi Sankyo Company Ltd, will merge with its US-based sister company, Asubio Pharmaceuticals Inc. As a result, Asubio Pharmaceuticals, Inc. projects will be integrated into the Daiichi Sankyo global development organization.

Asubio Pharmaceuticals' parent company, Asubio Pharma Co., Ltd, which is based in Japan, will continue to operate as a wholly owned subsidiary of Daiichi Sankyo Co., Ltd., with a focus on discovery research.

Asubio Pharmaceuticals Inc.'s ongoing clinical trial in patients with acute spinal cord injury, ASBI 603ASCENT Study (SUN13837) has completed enrolment. Analysis and dissemination of the data will be managed by Daiichi Sankyo.